Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
melperone
- Development stage
- Phase 2
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Intravenous
01
Overview
Melperone is an atypical antipsychotic of the butyrophenone chemical class and is structurally related to haloperidol. It has been used for over 30 years in the European Union for the treatment of sleep disorders, confusion states (especially in geriatric patients), psychomotor dysfunction associated with psychiatric and alcohol-dependent patients, severe agitation, schizophrenia-related psychosis (including treatment-resistant cases), anxiety disorders (with anxiolytic properties), and certain behavioral disorders. It is also considered for psychosis related to Parkinson’s disease. Melperone acts primarily as a dopamine D2 receptor antagonist with low affinity and rapid dissociation from D2 receptors; it also exerts effects on serotonin receptors (5-HT2A) contributing to its anxiolytic and mood-stabilizing effects. The drug is known for its relatively mild side effect profile compared to typical antipsychotics[1][3][7].
- Brand names
- BuronilEunerpanBunil
- Other names
- methylperonmetylperonMel-PurenMelneurinHarmosinLibernal
02
Targets
DRD2 (Dopamine D2 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)
Beyond the preview
Go deeper on melperone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on melperone.